Tag Archives: CNV

Collaboration column: SMA therapeutics and potential drug target for schizophrenia

CSHL researchers are part of two highly successful, multi-institutional collaborations that report exciting advances in developing therapeutics for a devastating neuromuscular disorder and in finding a ‘druggable’ target for schizophrenia. For several years now, CSHL’s Adrian Krainer has devoted his expertise in … Continue reading

Posted in Disease research, Genomics, Neuroscience | Tagged , , , , , | 1 Comment